194 related articles for article (PubMed ID: 18003811)
1. Safety and immunogenicity of two influenza virus subunit vaccines, with or without MF59 adjuvant, administered to human immunodeficiency virus type 1-seropositive and -seronegative adults.
Durando P; Fenoglio D; Boschini A; Ansaldi F; Icardi G; Sticchi L; Renzoni A; Fabbri P; Ferrera A; Parodi A; Bruzzone B; Gabutti G; Podda A; Del Giudice G; Fragapane E; Indiveri F; Crovari P; Gasparini R
Clin Vaccine Immunol; 2008 Feb; 15(2):253-9. PubMed ID: 18003811
[TBL] [Abstract][Full Text] [Related]
2. Superior immunogenicity of seasonal influenza vaccines containing full dose of MF59 (®) adjuvant: results from a dose-finding clinical trial in older adults.
Della Cioppa G; Nicolay U; Lindert K; Leroux-Roels G; Clement F; Castellino F; Galli G; Groth N; Del Giudice G
Hum Vaccin Immunother; 2012 Feb; 8(2):216-27. PubMed ID: 22426371
[TBL] [Abstract][Full Text] [Related]
3. Comparison between a conventional subunit vaccine and the MF59-adjuvanted subunit influenza vaccine in the elderly: an evaluation of the safety, tolerability and immunogenicity.
Sindoni D; La Fauci V; Squeri R; Cannavò G; Bacilieri S; Panatto D; Gasparini R; Amicizia D
J Prev Med Hyg; 2009 Jun; 50(2):121-6. PubMed ID: 20099444
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the immunogenicity and safety of the conventional subunit, MF59-adjuvanted, and intradermal influenza vaccines in the elderly.
Seo YB; Choi WS; Lee J; Song JY; Cheong HJ; Kim WJ
Clin Vaccine Immunol; 2014 Jul; 21(7):989-96. PubMed ID: 24828092
[TBL] [Abstract][Full Text] [Related]
5. Long-term immunogenicity after one and two doses of a monovalent MF59-adjuvanted A/H1N1 Influenza virus vaccine coadministered with the seasonal 2009-2010 nonadjuvanted Influenza virus vaccine in HIV-infected children, adolescents, and young adults in a randomized controlled trial.
Viganò A; Giacomet V; Pariani E; Giani E; Manfredini V; Bedogni G; Erba P; Amendola A; Zanetti A; Zuccotti G
Clin Vaccine Immunol; 2011 Sep; 18(9):1503-9. PubMed ID: 21795458
[TBL] [Abstract][Full Text] [Related]
6. Safety, Tolerability and Immunogenicity of an MF59-adjuvanted, Cell Culture-derived, A/H5N1, Subunit Influenza Virus Vaccine: Results From a Dose-finding Clinical Trial in Healthy Pediatric Subjects.
Chanthavanich P; Anderson E; Kerdpanich P; Bulitta M; Kanesa-Thasan N; Hohenboken M
Pediatr Infect Dis J; 2019 Jul; 38(7):757-764. PubMed ID: 31194712
[TBL] [Abstract][Full Text] [Related]
7. Response to 2009 pandemic and seasonal influenza vaccines co-administered to HIV-infected and HIV-uninfected former drug users living in a rehabilitation community in Italy.
Pariani E; Boschini A; Amendola A; Poletti R; Anselmi G; Begnini M; Ranghiero A; Cecconi G; Zanetti AR
Vaccine; 2011 Nov; 29(49):9209-13. PubMed ID: 21974995
[TBL] [Abstract][Full Text] [Related]
8. Dose ranging of adjuvant and antigen in a cell culture H5N1 influenza vaccine: safety and immunogenicity of a phase 1/2 clinical trial.
Keitel W; Groth N; Lattanzi M; Praus M; Hilbert AK; Borkowski A; Tsai TF
Vaccine; 2010 Jan; 28(3):840-8. PubMed ID: 19835829
[TBL] [Abstract][Full Text] [Related]
9. Immunogenicity and safety of the influenza A/H1N1 2009 inactivated split-virus vaccine in young and older adults: MF59-adjuvanted vaccine versus nonadjuvanted vaccine.
Cheong HJ; Song JY; Heo JY; Noh JY; Choi WS; Park DW; Wie SH; Kim WJ
Clin Vaccine Immunol; 2011 Aug; 18(8):1358-64. PubMed ID: 21715575
[TBL] [Abstract][Full Text] [Related]
10. Pandemic influenza A/H1N1 vaccine administered sequentially or simultaneously with seasonal influenza vaccine to HIV-infected children and adolescents.
Esposito S; Tagliaferri L; Daleno C; Valzano A; Picciolli I; Tel F; Prunotto G; Serra D; Galeone C; Plebani A; Principi N
Vaccine; 2011 Feb; 29(8):1677-82. PubMed ID: 21199699
[TBL] [Abstract][Full Text] [Related]
11. Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant.
Vesikari T; Pellegrini M; Karvonen A; Groth N; Borkowski A; O'Hagan DT; Podda A
Pediatr Infect Dis J; 2009 Jul; 28(7):563-71. PubMed ID: 19561422
[TBL] [Abstract][Full Text] [Related]
12. Serological responses to an avian influenza A/H7N9 vaccine mixed at the point-of-use with MF59 adjuvant: a randomized clinical trial.
Mulligan MJ; Bernstein DI; Winokur P; Rupp R; Anderson E; Rouphael N; Dickey M; Stapleton JT; Edupuganti S; Spearman P; Ince D; Noah DL; Hill H; Bellamy AR;
JAMA; 2014 Oct; 312(14):1409-19. PubMed ID: 25291577
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity of intramuscular MF59-adjuvanted and intradermal administered influenza enhanced vaccines in subjects aged over 60: A literature review.
Camilloni B; Basileo M; Valente S; Nunzi E; Iorio AM
Hum Vaccin Immunother; 2015; 11(3):553-63. PubMed ID: 25714138
[TBL] [Abstract][Full Text] [Related]
14. MF-59 adjuvant influence on the functions of gammadelta T cells in HIV-1+ adults immunized with influenza seasonal vaccine.
Fenoglio D; Zocchi MR; Parodi A; Durando P; Gabutitp G; Gasparini R; Poggi A
J Prev Med Hyg; 2011 Sep; 52(3):137-41. PubMed ID: 22010544
[TBL] [Abstract][Full Text] [Related]
15. Identification of antigen and adjuvant doses resulting in optimal immunogenicity and antibody persistence up to 1 year after immunization with a pandemic A/H1N1 influenza vaccine in children 3 to < 9 years of age.
Nassim C; Christensen S; Henry D; Holmes S; Hohenboken M; Kanesa-Thasan N
Pediatr Infect Dis J; 2012 Apr; 31(4):e59-65. PubMed ID: 22418661
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity and safety of cell-derived MF59®-adjuvanted A/H1N1 influenza vaccine for children.
Knuf M; Leroux-Roels G; Rümke H; Rivera L; Pedotti P; Arora AK; Lattanzi M; Kieninger D; Cioppa GD
Hum Vaccin Immunother; 2015; 11(2):358-76. PubMed ID: 25621884
[TBL] [Abstract][Full Text] [Related]
17. Efficacy, immunogenicity, and safety evaluation of an MF59-adjuvanted quadrivalent influenza virus vaccine compared with non-adjuvanted influenza vaccine in children: a multicentre, randomised controlled, observer-blinded, phase 3 trial.
Vesikari T; Kirstein J; Devota Go G; Leav B; Ruzycky ME; Isakov L; de Bruijn M; Oberye J; Heijnen E
Lancet Respir Med; 2018 May; 6(5):345-356. PubMed ID: 29631857
[TBL] [Abstract][Full Text] [Related]
18. A dose-ranging study in older adults to compare the safety and immunogenicity profiles of MF59®-adjuvanted and non-adjuvanted seasonal influenza vaccines following intradermal and intramuscular administration.
Della Cioppa G; Nicolay U; Lindert K; Leroux-Roels G; Clement F; Castellino F; Galli C; Groth N; Levin Y; Del Giudice G
Hum Vaccin Immunother; 2014; 10(6):1701-10. PubMed ID: 24732325
[TBL] [Abstract][Full Text] [Related]
19. MF59-adjuvanted influenza vaccine (FLUAD) in children: safety and immunogenicity following a second year seasonal vaccination.
Vesikari T; Groth N; Karvonen A; Borkowski A; Pellegrini M
Vaccine; 2009 Oct; 27(45):6291-5. PubMed ID: 19840662
[TBL] [Abstract][Full Text] [Related]
20. Safety and immunogenicity of a monovalent MF59®-adjuvanted A/H1N1 vaccine in HIV-infected children and young adults.
Palma P; Romiti ML; Bernardi S; Pontrelli G; Mora N; Santilli V; Tchidjou HK; Aquilani A; Cotugno N; Alghisi F; Lucidi V; Rossi P; Douagi I
Biologicals; 2012 Mar; 40(2):134-9. PubMed ID: 22261282
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]